J. H. Lipton

2.7k total citations
29 papers, 808 citations indexed

About

J. H. Lipton is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, J. H. Lipton has authored 29 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 14 papers in Genetics and 6 papers in Oncology. Recurrent topics in J. H. Lipton's work include Chronic Lymphocytic Leukemia Research (13 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Hematopoietic Stem Cell Transplantation (7 papers). J. H. Lipton is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Hematopoietic Stem Cell Transplantation (7 papers). J. H. Lipton collaborates with scholars based in Canada, United States and Germany. J. H. Lipton's co-authors include Hans A. Messner, Atul Humar, Tony Mazzulli, Thomas Kiss, Mary M. Horowitz, Michael Gratwohl, Jakob Passweg, Helen Baldomero, Mahmoud Aljurf and Y Kodera and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Infectious Diseases and Leukemia.

In The Last Decade

J. H. Lipton

29 papers receiving 787 citations

Peers

Countries citing papers authored by J. H. Lipton

Since Specialization

Citations

This map shows the geographic impact of J. H. Lipton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. H. Lipton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. H. Lipton more than expected).

Fields of papers citing papers by J. H. Lipton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. H. Lipton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. H. Lipton. The network helps show where J. H. Lipton may publish in the future.

Co-authorship network of co-authors of J. H. Lipton

This figure shows the co-authorship network connecting the top 25 collaborators of J. H. Lipton. A scholar is included among the top collaborators of J. H. Lipton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. H. Lipton. J. H. Lipton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PF411 ENESTOP 192‐WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) FOLLOWING SECOND‐LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML) 2019 ·HemaSphere ·François‐Xavier Mahon, Carla Boquimpani, (unknown), Noam Benyamini, Nelma Clementino, Vasily Shuvaev, J. H. Lipton, Anna Turkina, Raquel De Paz Arias, Beatriz Moiraghi, Franck E. Nicolini, Jolanta Dengler, Tomasz Sacha, (unknown), (unknown), (unknown), (unknown), Timothy P. Hughes	1
2	Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results 2017 ·Leukemia ·Timothy P. Hughes, Brian Leber, Francisco Cervantes, Nelson Spector, Ricardo Pasqüini, Nelma Clementino, Anthony P. Schwarer, P.E. Dorlhiac‐Llacer, F-X Mahon, Delphine Réa, A. Guerci-Bresler, Suzanne Kamel‐Reid, Israel Bendit, (unknown), (unknown), Darshan Dalal, Susan Branford, J. H. Lipton	31
3	Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey 2016 ·Bone Marrow Transplantation ·D Niederwieser, Helen Baldomero, Jeff Szer, Michael Gratwohl, Mahmoud Aljurf, Yoshiko Atsuta, Luís Fernando S. Bouzas, Dennis L. Confer, Hildegard Greinix, Mary M. Horowitz, Minako Iida, J. H. Lipton, Mohamad Mohty, Nicolás Novitzky, (unknown), Jakob Passweg, Marcelo C. Pasquini, Y Kodera, Jane Apperley, Adriana Seber, A Gratwohl, (unknown)	198
4	Smoothened (Smo) Inhibitor Lde225 Combined With Nilotinib In Patients With Chronic Myeloid Leukemia (Cml) Resistant/Intolerant (R/I) To At Least 1 Prior Tyrosine Kinase Inhibitor: A Phase 1B Study 2015 ·ORCA Online Research @Cardiff (Cardiff University) ·Oliver G. Ottmann, A Charbonnier, Frank Stegelmann, Massimo Breccia, J. L. Steegmann, Eduardo Olavarría, (unknown), (unknown), Nicolas Scheuer, J. H. Lipton	4
5	Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors 2014 ·Leukemia Research ·J. H. Lipton, Peter Bryden, M. Sidhu, Hui Huang, Lisa J. McGarry, Stephanie Lustgarten, Stuart Mealing, Beth Woods, Jo Whelan, Neil Hawkins	38
6	Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study 2013 ·Haematologica ·Aloïs Gratwohl, Helen Baldomero, Michael Gratwohl, Mahmoud Aljurf, Luís Fernando S. Bouzas, Mary M. Horowitz, Y Kodera, J. H. Lipton, Minako Iida, Marcelo C. Pasquini, Jakob Passweg, Jeff Szer, J. Alejandro Madrigal, Karl Frauendorfer, D. Niederwieser, (unknown)	67
7	Case Report of Very Late Gastric Cancer Recurrence 2013 ·Current Oncology ·Phillip Blanchette, J. H. Lipton, David Barth, Helen Mackay	9
8	A global phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD). 2011 ·Journal of Clinical Oncology ·Jason Gotlib, Hanneke C. Kluin‐Nelemans, Michael J. Mauro, Olivier Hermine, Elizabeth O. Hexner, J. H. Lipton, Farrukh T. Awan, Zariana Nikolova, (unknown), Catherine Dutreix, B. Dharan, (unknown), (unknown), Cem Akin, Katrin Hartmann, Peter Valent, Andreas Reiter, (unknown)	2
9	Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) 2008 ·Journal of Clinical Oncology ·Michael J. Mauro, Michele Baccarani, Francisco Cervantes, J. H. Lipton, Yousif Matloub, (unknown), Richard M. Stone	60
10	208: Impact of posaconazole (POS) vs fluconazole (FLU) on cyclosporine (CsA) and tacrolimus (TAC) dosing in hematopoietic stem cell transplant (HSCT) recipients with graft-vs-host disease (GVHD) 2007 ·Biology of Blood and Marrow Transplantation ·Amelia Langston, J. H. Lipton, Thomas M. Brundage, Hernando Patino, Andrew J. Ullmann	1
11	Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation 2004 ·Bone Marrow Transplantation ·Wanda Hasegawa, Gregory R. Pond, (unknown), Hans A. Messner, Anthea Lau, Andrew Daly, Thomas Kiss, (unknown), (unknown), J. H. Lipton	70
12	Bone marrow aspirates as part of routine donor assessment for allogeneic blood and marrow transplantation can reveal presence of occult hematological malignancies in otherwise asymptomatic individuals 2004 ·Bone Marrow Transplantation ·Thomas Kiss, Hong Chang, Andrew Daly, Hans A. Messner, N Jamal, David Spaner, (unknown), J. H. Lipton	16
13	Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma 2003 ·Bone Marrow Transplantation ·Thomas Kiss, Tony Panzarella, Hans A. Messner, J. Meharchand, Vijay Reddy, Aaron D. Schimmer, J. H. Lipton	25
14	Association of Familial Leukemia with HLA Cw3: Is it Real? 2002 ·Leukemia & lymphoma ·John Kuruvilla, Vikas Gupta, Kamaldeep Gill, J. H. Lipton	7
15	Pulmonary function abnormalities after allogeneic marrow transplantation: a systematic review and assessment of an existing predictive instrument 2002 ·Bone Marrow Transplantation ·(unknown), J. P. Szalai, (unknown), J. H. Lipton, (unknown), Andreas Laupacis	45
16	A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients 2001 ·Bone Marrow Transplantation ·Atul Humar, J. H. Lipton, Sandy Welsh, George Moussa, Hans A. Messner, Tony Mazzulli	17
17	Elevated Serum Cytokines Are Associated with Cytomegalovirus Infection and Disease in Bone Marrow Transplant Recipients 1999 ·The Journal of Infectious Diseases ·Atul Humar, Patrick St. Louis, Tony Mazzulli, Allison McGeer, J. H. Lipton, Hans A. Messner, Kelly S. MacDonald	71
18	Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective 1998 ·Bone Marrow Transplantation ·Stephen Couban, George Dranitsaris, Pantelis Andreou, (unknown), (unknown), Ronan Foley, (unknown), (unknown), N Jamal, David Spaner, J. H. Lipton, J. Meharchand, HA Messner	18
19	The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation 1998 ·Bone Marrow Transplantation ·Atul Humar, Keith O’Rourke, J. H. Lipton, Hans A. Messner, J. Meharchand, James B. Mahony, I. Walker, Parveen Wasi, Allison McGeer, George Moussa, Robert Lorenz Chua, Tony Mazzulli	14
20	Pneumatosis intestinalis with free air mimicking intestinal perforation in a bone marrow transplant patient. 1994 ·PubMed ·J. H. Lipton, (unknown), Robert A. Mustard, (unknown), Gillian Fyles, J. Meharchand, Hans A. Messner	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact